Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoveren Scientific, Inc.MDVX · Entity 95079 | Director | October 30, 2017 | November 01, 2017 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director | December 31, 2018 | February 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoveren Scientific, Inc.
Report date October 30, 2017 · Filed November 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 228,136 |
Reported balance
After 2017-10-30 transaction · row 1
1 source rowRow 1 · 2017-10-30 · Grant · Acquired 12,821 · Balance 228,136 F1: The Reporting Person was granted 12,821 shares of common stock in lieu of cash fees that were due to the Reporting Person as of September 30, 2017 for his board services. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during the nine months ended 2017, divided by the average closing price of the Issuer's common stock during the nine months ended 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 12,821 shares of common stock in lieu of cash fees that were due to the Reporting Person as of September 30, 2017 for his board services. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during the nine months ended 2017, divided by the average closing price of the Issuer's common stock during the nine months ended 2017.
MIMEDX GROUP, INC.
Report date December 31, 2018 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectTrust | 41,667 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 41,667 |
| Common StockSEC Table I · non-derivative | Direct | 98,491 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 98,491 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2020-05-10 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2021-12-13 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 15,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2022-10-30 | Direct | 27,000 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 27,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2023-05-08 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 15,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.28 · Expires 2024-07-27 | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 15,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
REAVES UTILITY INCOME FUND
Report date October 31, 2021 · Filed June 14, 2022
Section 16 reporting ended · disclosed 2022-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial OwnershipSEC Table I · non-derivative | Direct | 3,745 |
Reported balance
Holding disclosure · report date 2021-10-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,745 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2017 Filed Nov 1, 2017 18:32 UTC | Innoveren Scientific, Inc. MDVX · Entity 95079 | GrantCommon Stock | 12,821 | $1.17 | $15,000.57 |
DisclosureSEC source: 0001493152-17-012286 · form4.xml · nonDerivative · entry 1 PAPASAN LARRY W · CIK 0001281239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,136 F1 · shares: The Reporting Person was granted 12,821 shares of common stock in lieu of cash fees that were due to the Reporting Person as of September 30, 2017 for his board services. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during the nine months ended 2017, divided by the average closing price of the Issuer's common stock during the nine months ended 2017. F1 · price: The Reporting Person was granted 12,821 shares of common stock in lieu of cash fees that were due to the Reporting Person as of September 30, 2017 for his board services. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during the nine months ended 2017, divided by the average closing price of the Issuer's common stock during the nine months ended 2017. Read SEC document |
| August 31, 2017 Filed Feb 6, 2018 21:05 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GiftCommon Stock | 4,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-18-000004 · wf-form5_151795113414880.xml · nonDerivative · entry 2 PAPASAN LARRY W · CIK 0001281239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,158 F1 · kind: This transaction was a gift. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:21 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GrantCommon Stock | 12,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-17-000099 · wf-form4_149522525493544.xml · nonDerivative · entry 1 PAPASAN LARRY W · CIK 0001281239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,042 F1 · shares: Grant of restricted stock which vests in full on the first anniversary date of the grant. Read SEC document |
| March 24, 2017 Filed Feb 6, 2018 21:05 UTC | MIMEDX GROUP, INC. MDXG · Entity 5271 | GiftCommon Stock | 2,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001376339-18-000004 · wf-form5_151795113414880.xml · nonDerivative · entry 1 PAPASAN LARRY W · CIK 0001281239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,082 F1 · kind: This transaction was a gift. Read SEC document |
| January 12, 2017 Filed Jan 20, 2017 12:46 UTC | Innoveren Scientific, Inc. MDVX · Entity 95079 | GrantCommon Stock | 21,739 | $1.38 | $29,999.82 |
DisclosureSEC source: 0001415889-17-000118 · form4-01202017_090128.xml · nonDerivative · entry 1 PAPASAN LARRY W · CIK 0001281239 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,815 F1 · price: The Reporting Person was granted 21,739 shares of common stock in lieu of cash fees that were due to the Reporting Person as of December 31, 2016 for his board services during fiscal years 2015 and 2016. The number of shares issued is based on the accrued but unpaid director fees owed to the Reporting Person during fiscal years 2015 and 2016, divided by average closing price of the Issuer's common stock during fiscal year 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.